Genetic Testing8 min read

The GARS test is gone - What replaced it (and why its better)

If you've been searching for the Genetic Addiction Risk Score test and coming up empty, here's exactly what happened — and where to go instead.

If you've been searching for the GARS test — the Genetic Addiction Risk Score developed by Dr. Kenneth Blum and Geneus Health — you've probably noticed something: it's gone. This has left a lot of people confused, especially those who were referred to the GARS test by addiction specialists, therapists, or family members who remember it from just a few years ago. The science behind it is real, the need for it hasn't gone away — but the original product is no longer available.

What Was the GARS Test?

The Genetic Addiction Risk Score was a DNA-based assessment that analyzed a panel of reward pathway genes to estimate an individual's vulnerability to addiction. It was developed over 25 years of research by Dr. Kenneth Blum — whose landmark 1990 study in JAMA was the first confirmed gene association in psychiatric genetics, linking the DRD2 dopamine receptor gene to severe alcoholism.

The GARS test analyzed 10 reward genes across 11 key SNPs (single nucleotide polymorphisms) in the Brain Reward Cascade — the chain of neurotransmitter interactions that produces dopamine at the brain's reward center. People who carry certain combinations of these gene variants are measurably more vulnerable to addictive behaviors, not because of weak character, but because of neurochemistry.

The science is solid. The GARS panel is backed by thousands of peer-reviewed studies and was used clinically by addiction specialists across the country. What it wasn't was a consumer-friendly, actionable product — and that's exactly where the gap exists today.

What Replaced It — And Why It's Better

AddictionDNA was built specifically to fill this gap. The platform pairs the same foundational reward gene science with something the original GARS product never offered: a complete, personalized protocol for what to actually do with your results.

The DNA assessment available through AddictionDNA goes beyond the original GARS panel. It analyzes reward pathway genes — including DRD1, DRD2, DRD3, DRD4, DAT1, COMT, MTHFR, OPRM1, and others — and delivers a report that tells you not just your risk level, but why your risk is elevated and what genetic pathways are involved.

More importantly, the assessment connects to a complete downstream protocol: supplement recommendations matched to your specific gene variants, optional 1:1 consultation to walk through your results, and coaching support to implement the recommended changes.

This is a fundamentally different kind of information than what you get from a blood panel or biomarker screening. Blood tests capture a moment in time. Your DNA reveals what has always been true — and always will be. The same gene variants that shaped your risk at birth are the same ones your report will identify today.

GARS vs. AddictionDNA Assessment

DNA reward gene panel✓ Yes (10 genes)✓ Yes (expanded panel)
Consumer-direct access✗ Limited✓ Yes
Results consultation✗ No✓ Optional add-on
Matched supplement protocol✗ No✓ Included
Ongoing coaching✗ No✓ Available
Actionable next steps✗ Report only✓ Full protocol

Who Should Get Tested?

The DNA assessment is relevant for a broader group of people than most expect. You don't need to have an active addiction to benefit — in fact, the prevention use case is where the test is arguably most powerful.

People with a family history of addiction

Genetic risk is heritable. If a parent, sibling, or grandparent struggled with substance use, your own reward genes may carry similar variants. Knowing this before a problem develops is the most powerful use of this information.

People in recovery

Understanding the genetic basis of your addiction doesn’t just explain why the battle has been hard — it points to personalized interventions. The right supplement protocol for your specific gene variants can meaningfully support long-term sobriety.

People with ADHD, anxiety, or mood disorders

These conditions share significant genetic overlap with addiction risk. They often co-occur because they involve the same reward pathway variants. Treating one without understanding the genetics often means treating symptoms rather than causes.

Anyone curious about their dopamine baseline

Reward Deficiency Syndrome doesn’t only manifest as substance addiction. It can show up as compulsive eating, gambling, excessive social media use, or simply a persistent low-level feeling that everyday life isn't satisfying enough. The genetic picture illuminates all of these.

The Bottom Line

The GARS test was a genuine scientific breakthrough that never quite made it to the people who needed it most. AddictionDNA is the direct continuation of that work — the same foundational science, expanded gene panel, and for the first time, a complete pathway from test to protocol to support.

If you were looking for the GARS test, you've found the right place.

Ready to understand your genetic risk?

Start with our free 10-question risk assessment, or go straight to the DNA test for a complete picture.

Take Free Quiz →Get DNA Assessment